Holen Sie sich die Stockscreener-App
10.38
1.33%
-0.14
Handel nachbörslich:
10.42
0.04
+0.39%
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Intellia Updates Investors on Nex-Z Trial Safety Hold - TipRanks
Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets
Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru
CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - MarketScreener
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union
44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan
What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
Why Intellia Therapeutics (NTLA) Is Down After FDA Halts Key CRISPR Trial Over Safety Concerns – And What's Next - Sahm
BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - MarketScreener
Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz
Intellia Therapeutics reports inducement grants - Medical Buyer
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Big Picture: Can Intellia Therapeutics Inc stock beat analyst upgradesJuly 2025 Momentum & Daily Technical Stock Forecast Reports - moha.gov.vn
Trading the Move, Not the Narrative: (NTLA) Edition - Stock Traders Daily
Short Squeeze: Is Intellia Therapeutics Inc stock a defensive play in 20252025 Support & Resistance & Real-Time Chart Breakout Alerts - moha.gov.vn
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood shells out $1.3 million on biotech stock - Yahoo Finance
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - Yahoo Finance
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku By Investing.com - Investing.com South Africa
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku - Investing.com
What makes Intellia Therapeutics (NTLA) an interesting investment? - MSN
What Makes Intellia Therapeutics (NTLA) an Interesting Investment? - Finviz
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Voya Investment Management LLC Trims Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Intellia Therapeutics (NASDAQ:NTLA) Cut to "Sell" at Wall Street Zen - MarketBeat
Is Intellia Therapeutics Inc 38I a good long term investmentExit Strategy Tips & Download Our Free Trading Blueprint - earlytimes.in
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteTrade Ideas & Long-Term Growth Plans - ulpravda.ru
Intellia Therapeutics Earnings Notes - Trefis
Will Intellia Therapeutics Inc. stock continue dividend increasesJuly 2025 Momentum & Stepwise Trade Signal Implementation - DonanımHaber
Will Intellia Therapeutics Inc. (38I) stock hit analyst forecastsJuly 2025 Retail & Weekly High Momentum Picks - DonanımHaber
Is Intellia Therapeutics Inc. stock a top momentum play2025 Stock Rankings & Accurate Buy Signal Alerts - DonanımHaber
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 152.61% Potential Upside in Gene Editing Revolution - DirectorsTalk Interviews
Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - Улправда
Intellia Therapeutics (NTLA) Receives a Buy from Leerink Partners - The Globe and Mail
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc - MarketBeat
Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):